Want to see CELU full AI Analyst Report?
Celularity (CELU) AI Stock Analysis
Celularity
(NASDAQ:CELU)
Severely weak financials with negative equity and losses are the dominant factors, reinforced by bearish technicals and poor valuation metrics. Recent corporate events provide limited positive offset but do not materially improve the high-risk profile.
Celularity (CELU) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $25.96M
- Dividend Yield
- ―
- Average Volume (3M)
- 3.92M
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 3.39
- Revenue Growth
- -58.14%
- EPS Growth
- 47.25%
- Country
- US
- Employees
- 115
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Celularity Business Overview & Revenue Model
Company Description
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditio...
How the Company Makes Money
Celularity’s publicly described revenue model is based on (1) advancing its placental-derived allogeneic cell therapy pipeline toward commercialization and (2) monetizing its platforms through collaborations and other commercial arrangements. Specifi...
Celularity Financial Statement Overview
Summary
Very low income statement, balance sheet, and cash flow scores reflect volatile revenue, negative equity, persistent net losses, and ongoing cash burn, indicating severe financial distress.
Income Statement
24NegativeBalance Sheet
13Very NegativeCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.67M | 26.55M | 54.22M | 22.77M | 17.98M | 21.34M |
| Gross Profit | 3.59M | 6.48M | 39.23M | 6.75M | -1.69M | 11.68M |
| EBITDA | -36.19M | -77.66M | -43.71M | -183.95M | -138.83M | -88.11M |
| Net Income | -45.86M | -91.72M | -57.89M | -196.29M | 14.19M | -100.12M |
Balance Sheet | ||||||
| Total Assets | 96.17M | 107.33M | 132.68M | 143.89M | 401.07M | 414.13M |
| Cash, Cash Equivalents and Short-Term Investments | 586.00K | 6.17M | 738.00K | 227.00K | 13.97M | 37.24M |
| Total Debt | 36.02M | 40.90M | 68.84M | 65.42M | 65.59M | 31.14M |
| Total Liabilities | 131.70M | 145.39M | 123.84M | 102.93M | 202.16M | 314.71M |
| Stockholders Equity | -35.53M | -38.06M | 8.84M | 40.96M | 198.90M | 99.42M |
Cash Flow | ||||||
| Free Cash Flow | -8.92M | -13.25M | -6.56M | -42.73M | -143.11M | -116.30M |
| Operating Cash Flow | -8.92M | -13.25M | -6.40M | -38.69M | -137.88M | -110.10M |
| Investing Cash Flow | 0 | 0 | 514.00K | -4.05M | -5.24M | -5.90M |
| Financing Cash Flow | 8.38M | 18.65M | 6.70M | 24.09M | 119.84M | 98.56M |
Celularity Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELU, the sentiment is Negative. The current price of 0.80 is below the 20-day moving average (MA) of 1.21, below the 50-day MA of 1.32, and below the 200-day MA of 1.09, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 35.91 is Neutral, neither overbought nor oversold. The STOCH value of 30.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CELU.
Celularity Risk Analysis
Celularity disclosed 76 risk factors in its most recent earnings report. Celularity reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksCelularity Peers Comparison
Overall Rating
STTK45Neutral- CELU43Neutral
LTRN39Underperform
FBLG37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| STTK | 45Neutral | $558.02M | -10.90 | -43.57% | ― | -66.63% | 57.89% |
| CELU | 43Neutral | $25.96M | -0.45 | 142.25% | ― | -58.14% | 47.25% |
| LTRN | 39Underperform | $9.87M | -0.41 | -456.35% | ― | ― | 9.68% |
| FBLG | 37Underperform | $6.19M | -0.15 | -536.78% | ― | ― | 22.10% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CELU | Celularity Inc. | 0.80 | -0.92 | -53.49% | |
| LTRN | Lantern Pharma, Inc. | 0.66 | -3.16 | -82.72% | |
| STTK | Shattuck Labs, Inc. | 5.56 | 3.57 | 179.40% | |
| FBLG | FibroBiologics, Inc. | 0.93 | -6.96 | -88.22% |
Celularity Corporate Events
Celularity Partners with Vesalius on U.S. Peptide Manufacturing
PositiveOn October 29, 2026, Celularity and Vesalius Longevity Labs announced an exclusive manufacturing collaboration to create a first-of-its-kind U.S.-based final-stage manufacturing and supply platform for Vesalius’s Peptual-branded peptide active...
Celularity adds Naveen Jain amid strategic recapitalization
PositiveOn Sept. 29, 2026, Celularity announced that Naveen Jain, founder and CEO of Viome Life Sciences, will join its Board of Directors following completion of required regulatory procedures. Jain, a serial entrepreneur whose ventures span InfoSpace, Inte...
Celularity Secures New Convertible Note Financing and Board Shift
NeutralOn September 23–24, 2026, Celularity Inc. entered into a securities purchase agreement enabling up to $25 million of senior secured convertible notes and accompanying warrants in two tranches and closed an initial $11.01 million tranche at a $1...
Celularity Restores Nasdaq Compliance on Key Listing Standards
PositiveOn September 11, 2026, Celularity Inc. said it had regained compliance with Nasdaq’s minimum bid price requirement and the minimum market value of listed securities standard, leading Nasdaq to close both deficiency matters. The company still fa...
Celularity Announces Sudden Exit of Chief Commercial Officer
NegativeOn August 5, 2026, Celularity Inc. terminated the employment of Rick Gonzalez, who had been serving as the company’s Chief Commercial Officer, effective immediately. The abrupt departure of a key commercial executive may signal a shift in Celul...
Celularity Faces Nasdaq Listing Compliance Bid-Price Warning
NegativeOn July 23, 2026, Celularity Inc. received notice from Nasdaq that its Class A common stock no longer meets the exchange’s minimum bid price requirement, after trading below $1.00 per share for 30 consecutive business days. The stock continues...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026